AtriCure, Inc. 致力于心脏组织外科消融技术及左心耳闭合系统的研发、生产和销售。公司总部位于俄亥俄州梅森,目前拥有1300名全职员工。该公司于2005年8月5日首次公开募股(IPO)。其心脏消融和左心耳管理(LAAM)产品被医生用于开胸和微创心脏手术中。该公司的疼痛管理解决方案可在心血管或胸部外科手术期间用于冷冻神经。用于开胸和微创消融的产品包括Isolator Synergy钳子和多功能笔以及线性消融装置。用于开胸消融的产品包括cryoICE冷冻消融系统。用于微创消融的产品包括采用VisiTrax技术的EPi-Sense引导凝固系统。其心耳管理产品包括AtriClip系统。Isolator Synergy消融系统的钳子为一次性使用的射频(RF)耗材,其钳口以平行方式闭合。
How did ATRC's recent EPS compare to expectations?
The most recent EPS for AtriCure Inc is $0.0, 超出预期 expectations of $-0.06.
How did AtriCure Inc ATRC's revenue perform in the last quarter?
AtriCure Inc revenue for the last quarter is $0.0
What is the revenue estimate for AtriCure Inc?
According to 11 of Wall street analyst, the revenue estimate of AtriCure Inc range from $160.65M to $145.63M
What's the earning quality score for AtriCure Inc?
AtriCure Inc has a earning quality score of B+/52.015045. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does AtriCure Inc report earnings?
AtriCure Inc next earnings report is expected in 2026-08-03
What are AtriCure Inc's expected earnings?
AtriCure Inc expected earnings is $142.6M, according to wall-street analysts.
Did AtriCure Inc beat earnings expectations?
AtriCure Inc recent earnings of $141.24M 未达预期 expectations.